Despite its rarity in the United States, sickle cell disease accounts for a disproportionate amount of healthcare utilization and costs. The majority of this is due to acute care for painful crises. A small subpopulation of patients accounts for most these costs due to frequent visits to emergency departments and acute care facilities. Previous investigations have found that these high utilizing patients are distinguished by both a more severe disease course and certain nonhematologic characteristics, which may include higher socioeconomic status and some psychiatric and psychological characteristics. This prospective observational cohort study was undertaken to test the ability of these characteristics to prospectively predict acute pain care outcomes, including visit frequency, total opioid doses, and pain improvement at the Johns Hopkins Sickle Cell Infusion Center (SCIC). Seventy-three participants were followed for 12 months and SCIC utilization and treatment outcomes were tabulated for 378 visits. Participants who visited the SCIC most frequently had markedly worse pain improvement despite higher within-visit opioid doses. Higher utilization was associated with indicators of greater illness severity, more aggressive treatment for sickle cell disease, higher baseline opioid doses, higher socioeconomic status, greater pain-related anxiety, and a history of psychiatric treatment. Overall, poor acute pain treatment response was associated with higher utilization and higher baseline opioid doses.
Despite its rarity in the United States, sickle cell disease accounts for a disproportionate amount of healthcare utilization and costs. The majority of this is due to acute care for painful crises. A small subpopulation of patients accounts for most these costs due to frequent visits to emergency departments and acute care facilities. Previous investigations have found that these high utilizing patients are distinguished by both a more severe disease course and certain nonhematologic characteristics, which may include higher socioeconomic status and some psychiatric and psychological characteristics. This prospective observational cohort study was undertaken to test the ability of these characteristics to prospectively predict acute pain care outcomes, including visit frequency, total opioid doses, and pain improvement at the Johns Hopkins Sickle Cell Infusion Center (SCIC). Seventy-three participants were followed for 12 months and SCIC utilization and treatment outcomes were tabulated for 378 visits. Participants who visited the SCIC most frequently had markedly worse pain improvement despite higher within-visit opioid doses. Higher utilization was associated with indicators of greater illness severity, more aggressive treatment for sickle cell disease, higher baseline opioid doses, higher socioeconomic status, greater pain-related anxiety, and a history of psychiatric treatment. Overall, poor acute pain treatment response was associated with higher utilization and higher baseline opioid doses.
The pattern of association between high utilization, poor acute care outcomes, and higher baseline opioid doses is discussed in terms of prior research and future directions.
| INTRODUCTION
Sickle cell disease (SCD) is an autosomal recessive hereditary hemoglobinopathy producing complex multi-system damage, morbidity, and early mortality. There are approximately 100 000 people living with SCD in the United States. Painful vaso-occlusive crises (VOC) are the most common complication associated with SCD. The pain of vaso-occlusive crisis is severe and highly unpredictable. There are no objective markers for the presence or severity of VOC beyond a patient's report of crisis pain, which often requires parenteral opioids for pain control along with other supportive measures. In addition to crisis pain, adults with SCD suffer a heavy burden of non-crisis and chronic pain, the mechanisms for which are obscure and likely highly complex. 4 Despite the burden of both chronic and acute pain imposed by SCD, typical SCD patients manage most of their crises at home, with relatively infrequent emergency department visits. 5, 6 However, hospital costs for the care of SCD are exceptionally high. [7] [8] [9] [10] This paradox is explained by the skewed distribution of hospital utilization in SCD.
A small proportion of patients, generally between 10% and 20 %, have much more frequent visits and account for over 50% of all admissions and costs. 5, [10] [11] [12] [13] Although objective markers of disease severity are associated with acute care visits, 1,10,12 they only partially explain differences in utilization. 14, 15 In prior pilot research by our group, 16 
| Opioid dose
Throughout the course of treatment for a painful crisis in the SCIC, medication used for pain was tracked alongside pain ratings by nursing staff using redundant documentation. After these visits, the medical record was used to record opioid dosing (medication, dose, and route) for each administration. These were converted to oral morphine equivalents using standard conversion tables. Opioid dosing in the SCIC is individualized based principally on prior patient history and response, as well as opioid tolerance. For those receiving parenteral opioids, hydromorphone is most typically used in multiples of 2 mg per dose (maximum single dose noted to be 6 mg intravenously [iv]), though for some participants morphine has been either more effective or better tolerated, and some participants were treated with 1 mg hydromorphine iv per dose due to known prior effectiveness. entered as a block to broadly control for disease severity and aggressiveness of treatment, but it was expected that straightforward interpretation of their individual effects in multivariate models would not be possible.
|

| Socioeconomic
Previous pilot studies suggested that high utilizing patients in our center had some indicators of higher socioeconomic status (SES), such as higher levels of parental education. Participants were asked to rate their own subjective socioeconomic status using the MacArthur Subjective Socioeconomic Scale (or MacArthur Ladder), 26 ,27 a measure using a visual analogy of a ladder to measure an individual's selfperceived SES. This was converted into a seven point numeric scale and the observed distribution closely approximated a normal distribution. Only the MacArthur Ladder was used in multivariate analyses as a measure of socioeconomic status since there was more missing data for maternal education.
| Psychiatric and substance use predictors
In a previous pilot study, high utilizing patients at the SCIC were more likely to report a family history of psychiatric illness and personal psychiatric treatment than were lower-utilizing patients. 16 As these factors are associated with more severe and refractory pain, 28 
| Pain related
Pain-related anxiety was measured using the 20-item version of the Pain Anxiety Symptom Scale (PASS-20). 24 The instrument was administered to all participants at baseline. Prescribed opioids are tracked in a clinical database. Outpatient opioid dosing was quantified by recording the last prescription for opioids, including long-and short-acting opioids. The strength was multiplied by the quantity dispensed, and divided by the number of days for which the prescription was intended to produce an average daily dose for each opioid. The average daily doses for each opioid were then converted to oral morphine equivalents and totaled. 
| Relationship of utilization to participant-level variables
Examination of scatterplots of visit time and visit number against SCIC outcomes suggested that higher visit numbers were related to poorer outcomes (see Figure 1) . To select an appropriate analysis method, we examined whether this effect was more related to individual partici- 
| Multivariate analyses
The relationships between participant characteristics at baseline and subsequent 12-month SCIC utilization were modeled using a generalized linear model with a negative binomial distribution due to the heavily skewed distribution of visits. Relationships between SCIC visit outcomes and participants' baseline characteristics were modeled using linear mixed-effects models. Individual participants were modeled as random effects, with all other predictors of interest modeled as fixed effects. Outcomes were pain improvement and within-visit opioid dose (as oral morphine equivalents). Because utilization and treatment response were so closely intertwined, utilization also was entered as a predictor in acute care outcomes models. This rendered the effect of utilization explicit as a fixed effect in the model (rather than its being folded in to participant characteristics as the random effects). After the full models for each outcome were fit, backward stepwise model reduction was performed (using R function drop1) to find the most parsimonious fixed effects models for each outcome (ie, that model including the subset of predictors which minimized AIC).
For convenience, individual predictors for which the P value was <.05
were considered "statistically significant," though the fundamental purpose of the study was exploratory. As noted below, post hoc multivariate linear models of baseline opioid dose were performed using simple linear models. All statistical analyses were performed using the R statistical computing environment. 31 3 | RESULTS
| Participant characteristics
A detailed description of participant characteristics is given in Table 1 .
Participants were typically in the early fourth decade of life, and there was a slight preponderance of women in the sample. Slightly fewer than three-quarters were of either SS or Sβ 0 genotype, and most had Utilization was modeled using negative binomial generalized linear modeling due to skew in the outcome measure. Pain improvement and within-visit opioid doses were modeled using linear mixed-effects models. Individual participants were modeled as random effects, with all other predictors of interest modeled as fixed effects. Simplified models were obtained by backward stepwise regression on the fixed-effects components of the models. 
| Relationship of utilization to acute care outcomes
The differences in visit outcomes between low-and high-utilizing participants were striking (see Table 1 ). Despite similar initial pain intensity, pain improvement was over twice as great for low-utilizing patients with fewer than five visits, yet they received less than half the total within-visit opioid dose as high utilizing patients (mean pain improvement 3.75 vs. 1.64, mean opioid dose 26.26 vs. 66.01 mg). It is generally accepted that at least a two point improvement in pain on a numeric rating scale is "clinically significant," and among this high utilizing group 49.5% of visits achieved that outcome, while 79.2% of low utilizers' visits met this goal. Although pain improvement was significantly worse for high utilizers, their SCIC visits overall were no less likely to result in discharge home. Also of note, the high utilizing group (31.5% of the total sample and half of those with at least one SCIC visit) accounted for 89.42% of all SCIC visits among study participants.
| Prospective predictors of SCIC utilization
See Table 2 , column 1 for a summary of multivariate prospective prediction of SCIC utilization during the study follow-up period. Acute chest syndrome, current chronic transfusion therapy, a history of hydroxyurea use, pain-related anxiety, higher socioeconomic status, personal psychiatric treatment, and higher baseline opioid doses all independently predicted greater visit numbers.
| Multivariate analyses of visit outcomes
In the full model predicting pain improvement which included utilization as a predictor, no single predictor was statistically significant (Table 2 ). However in the reduced model, a history of acute chest syndrome, greater baseline opioid dose, and greater utilization predicted reduced pain improvement. The full and simplified models predicting acute opioid dose were similar. In the reduced model, female gender, higher baseline opioid doses, and psychiatric family history all predicted higher acute opioid doses; whereas higher socioeconomic status predicted lower acute opioid doses. Because of the somewhat paradoxical associations of socioeconomic status with outcomes (higher utilization but reduced opioid doses) a post-hoc exploration was undertaken which suggested some effects were mediated by baseline opioid dose and utilization (see below). Pain-related anxiety also predicted greater utilization. The predictions based on personal psychiatric treatment and family history were complex. Psychiatric treatment was associated with higher utilization; though it is quite likely that those who are seen more frequently are more likely to be screened and diagnosed. Family psychiatric history also was strongly predictive of higher acute opioid dosing. In retrospect, it is possible that study exclusion criteria may have shifted these relationships, which adds another note of caution. Thirty-six prospective participants were not enrolled due to active severe psychiatric conditions (of a total of 67 who were approached but not enrolled). This criterion may have excluded the most vulnerable of participants who had a psychiatric family history, namely those who were themselves most severely ill. This relationship was complex as self-reported family psychiatric history also was associated with painrelated anxiety (mean 56.72 in those with psychiatric family history, mean 43.97 in those without, P = .029 in post hoc testing). It is almost certain that any relationship between family psychiatric history and SCD-related outcomes is indirect and mediated through more proximal elements such as coping, development of frank psychiatric illness, depressive symptoms, or anxiety-related phenomena.
Prior findings regarding associations between high utilization and higher socioeconomic status were replicated, and socioeconomic status appeared to be associated with greater baseline opioid doses as well, though independent of this it predicted lower acute opioid doses. Overall, however, the unexpected association of higher socioeconomic status with worsened outcomes noted in our pilot research seems to hold, and this further suggests that higher baseline opioid doses may mediate some of the adverse associations noted for socioeconomic status.
| Acute care treatment outcomes
In the full multivariate models, there were no strong individual predictors of pain improvement, but the more parsimonious model showed similar results as the simple bivariate relationships-there is a pattern of association among acute chest syndrome, higher baseline opioid dose, higher utilization, and worse acute pain outcomes.
Overall, psychological measures predicted higher utilization, but not worse acute pain outcomes independent of utilization. Of course, greater utilization itself was associated with worse acute care outcomes. Socioeconomic status, usually considered a protective factor for poor health outcomes, was positively associated with both higher utilization and higher baseline opioid doses which surprisingly suggest a worse long term course. In contrast, higher SES also independently predicted lower within-visit opioid doses but no difference in pain outcomes, which might be considered a good outcome. Any interpretation of such a contrasting set of findings is speculative at best. However, it is tempting to consider whether higher SES might be associated with greater access to care which might lead to a history of more aggressive pain treatment and more care seeking. 32 Socioeconomic status often is related to greater education-and by extension, probably intelligence and other adaptive traits-which is typically associated with a less severe pain experience and more adaptive coping. 33, 34 If socioeconomic status increases access to care but also improves pain experience, these seemingly contradictory findings might be reconciled. This hypothesis would require very thoughtful investigation to test.
| Common threads: Baseline opioid dose and high utilization
Total baseline opioid dose was related both to level of utilization and to poor pain improvement, despite higher opioid doses within visits.
Utilization level and baseline opioid dose in this study most likely mediated, in at least a statistical sense, the effects of most other predictors on acute care outcomes.
Among the participants with the highest baseline opioid dose, acute dosing was a fraction of baseline opioid dose and pain improvement tended to be poor; whereas for participants with low baseline opioid doses, intra-episode dosing was often greater than double standing outpatient doses and pain improvement was greater (see Figure 2 ). Assuming tolerance to analgesic effects is one mechanism for this, one practical note is that participants on low-dose opioids at baseline were likely to receive the equivalent of their entire daily home dose in a single typical parenteral dose of hydromorphone.
Patients at the maximal end of the baseline dose spectrum might require 10 times as much parenteral opioid to reach their home daily opioid dose-which poses both practical challenges in a brief acute care setting as well as a significant clinical conundrum in patients who also are frequently treated with apparently modest benefit.
Other investigators have noted stronger associations between psychological patient characteristics and non-crisis pain, rather than acute pain or utilization. 35 In particular, depressive symptoms are more consistently associated with greater non-crisis pain frequency and intensity, as well as more days of opioid use, though modestly less relief from opioids.
This study suggests a hypothesis to partly reconcile the different correlates of chronic and acute pain. If psychological patient characteristics exacerbate chronic pain or independently lead to higher baseline opioid doses, 29 they may indirectly impede acute pain treatment.
These adverse effects could be caused by increasing patients' baseline pain intensity thereby limiting the degree of improvement in an acute episode (a "floor effect" on pain intensity), reducing the effectiveness of acute opioid therapy through opioid tolerance, or some combination of both. The higher utilization noted in this population could be both cause and consequence of higher opioid doses, as poor response to home analgesics due to tolerance may lead to greater visit frequency but also serve as a source of opioid "dose creep." If the relationship between psychological factors and poor acute care outcomes is partly mediated by higher opioid doses, the nonlinear (ie, reciprocal) relationship between baseline opioid dose and treatment outcome might be difficult to detect with the linear statistical models often used in descriptive clinical research (see Figure 2 ).
This also points out a common problem in the management of SCD, as tolerance to opioids likely blunts analgesic response and necessitates higher doses of opioids for acute care. However, it is simultaneously true that high utilizing participants on high baseline doses of opioids had discouragingly little benefit from frequent treatments with higher doses of intravenous opioids. This raises concern for failure of opioid therapy in general in these participants. This conflict demonstrates a vexing clinical dilemma: whether to define this phenomenon as opioid failure, opioid-induced worsening/hyperalgesia, or inadequate dosing in the face of opioid tolerance. The latter argues for an opposite clinical response from the former two, yet evidence can be marshaled for all three possibilities, and they are not mutually exclusive.
| Future directions
This study's results highlight relationships among high utilization, pain-related anxiety, poor acute care treatment response, greater socioeconomic status, and higher baseline opioid doses. Social and psychological differences in the participants were much more strongly related to utilization than acute care treatment response. However, some of these nonhematologic characteristics were predictive of baseline opioid dose, which was associated with both utilization and poor treatment outcomes, suggesting indirect causal effects are possible. Research in chronic pain in general and SCD in particular support the plausibility of this hypothesis. 29, 35, 36 The relationship of baseline opioid dose to treatment outcome was expected. It is unsurprising that participants with chronic and more refractory pain should be both more tolerant to opioids and have more refractory acute pain. What was of greater interest was how robust that relationship was, in that baseline opioid dose emerged as the most consistent characteristic prospectively associated with both higher utilization and poor acute care response.
Again the relationship is likely to be quite complex, as higher opioid doses may be both cause and consequence of more severe and refractory pain. However, these findings do add urgency to consideration of the balance of risks and benefits to chronic opioid therapy, particularly at high doses, for a patient population so vulnerable to episodes of severe acute pain.
| Strengths and limitations
The study has a number of limitations, including the fact that it studied a modest number of participants at a single center, and some outcomes may be idiosyncratic to the population or practices at the center. This is particularly true of the Infusion Center, which itself is not a universally available intervention. However, the capacity to study those participants prospectively for a full 12 months, examining highly detailed treatment data, is a relative strength. On a pragmatic note, the study also involves a disorder that is rare in the United
States, and recruiting large samples can be quite difficult. The analysis was complex, particularly in that participants had differential levels of utilization, thus some participants had more information available regarding their treatment response than others. This is a problem imposed by the nature of the condition, and the statistical methods used addressed it by controlling for utilization differences with mixedeffects models. Finally, exclusion of some psychiatrically ill prospective participants may have biased results, particularly regarding effects of family psychiatric history.
The study also had significant strengths, particularly in the breadth of baseline participant characteristics that could be examined using multivariate methods, the prospective nature of the design, and the exceptional detail with which treatment outcomes could be examined. Results generally fit with previously-established findings regarding disease severity and utilization, and replicated some prior pilot work suggesting consistency even in the novel findings.
